In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
NEW YORK (Reuters Health) – The Prove-it sepsis assay (Mobidiag, Helsinki, Finland) is highly sensitive and specific in identifying bacterial species in blood samples and provides much faster…
NEW YORK (Reuters Health) – Breast cancer recurrence rates are lower with aromatase inhibitors than with tamoxifen, according to meta-analyses published online by the Journal of Clinical Oncology.…
NEW YORK (Reuters Health) – High-flow inhaled oxygen is an effective treatment for cluster headache attacks, investigators said in the Journal of the American Medical Association for December…
NEW YORK (Reuters Health) – Children who are disease-free 5 years after a cancer diagnosis are still at risk for recurrence for another 20 years or more, new…
NEW YORK (Reuters Health) – Abatacept, an agent that modifies the costimulatory signal required for T-cell activation, does not increase malignancy rates in patients with rheumatoid arthritis (RA),…
NEW YORK (Reuters Health) – Methadone is a safe, effective first- or second-line treatment of cancer pain, even in outpatients, a retrospective study suggests. Concerns over its long…
NEW YORK (Reuters Health) – For men with hot flushes from androgen suppression for prostate cancer, medroxyprogesterone appears to be the best option for relief, according to a…
A new study suggests that patient safety experts should focus as much of their attention on human factors as system factors if they want to reduce avoidable medical…
NEW YORK (Reuters Health) – New research suggests that high-dose vitamin D can be safely given to breast cancer patients with bone metastases, but it will not affect…
NEW YORK (Reuters Health) – Recombinant human erythropoietin (EPO) provides no benefit after acute ischemic stroke, and may even be dangerous, particularly in patients receiving systemic thrombolysis. These…
